MADRIGAL PHARMACEUTICALS, INC. Cash Flow Statement
MDGL / Health Care|12 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
MADRIGAL PHARMACEUTICALS, INC. used $190M in operating cash flow and negative free cash flow of $190M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$288.3M | -$465.9M | -$373.6M | -$295.4M | -$241.8M | -$202.2M | -$83.9M | -$32.8M | -$31.2M | -$26.4M | - | - |
| Depreciation & Amortization | $1.5M | $1.1M | $527.0K | $467.0K | $405.0K | $471.0K | $112.0K | $96.0K | $77.0K | $156 | $673.0K | $738.0K |
| Operating Cash Flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M | -$183.9M | -$157.6M | -$41.6M | -$25.5M | -$22.3M | -$17.6M | -$78.9M | -$54.1M |
| Capital Expenditures | $467.0K | $1.5M | $1.5M | $217.0K | $209.0K | $334.0K | $172.0K | $22.0K | $125.0K | $3.0K | $144.0K | $505.0K |
| Free Cash Flow | -$190.0M | -$457.0M | -$325.7M | -$225.1M | -$184.1M | -$157.9M | -$41.8M | -$25.5M | -$22.4M | -$17.6M | -$79.1M | -$54.6M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | $32.0K |
| FCF Margin | -19.8% | -253.7% | - | - | - | - | - | - | - | - | - | - |